122 related articles for article (PubMed ID: 38215590)
21. Curcumin is an inhibitor of p300 histone acetylatransferase.
Marcu MG; Jung YJ; Lee S; Chung EJ; Lee MJ; Trepel J; Neckers L
Med Chem; 2006 Mar; 2(2):169-74. PubMed ID: 16787365
[TBL] [Abstract][Full Text] [Related]
22. A Small Molecule Activator of p300/CBP Histone Acetyltransferase Promotes Survival and Neurite Growth in a Cellular Model of Parkinson's Disease.
Hegarty SV; O'Leary E; Solger F; Stanicka J; Sullivan AM; O'Keeffe GW
Neurotox Res; 2016 Oct; 30(3):510-20. PubMed ID: 27256286
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
24. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
25. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
26. Multiple roles for acetylation in the interaction of p300 HAT with ATF-2.
Karanam B; Wang L; Wang D; Liu X; Marmorstein R; Cotter R; Cole PA
Biochemistry; 2007 Jul; 46(28):8207-16. PubMed ID: 17590016
[TBL] [Abstract][Full Text] [Related]
27. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity.
Ray S; Sherman CT; Lu M; Brasier AR
Mol Endocrinol; 2002 Apr; 16(4):824-36. PubMed ID: 11923478
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation.
Stiehl DP; Fath DM; Liang D; Jiang Y; Sang N
Cancer Res; 2007 Mar; 67(5):2256-2264. PubMed ID: 17332356
[TBL] [Abstract][Full Text] [Related]
29. CBP/p300 double null cells reveal effect of coactivator level and diversity on CREB transactivation.
Kasper LH; Lerach S; Wang J; Wu S; Jeevan T; Brindle PK
EMBO J; 2010 Nov; 29(21):3660-72. PubMed ID: 20859256
[TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells.
Yan G; Eller MS; Elm C; Larocca CA; Ryu B; Panova IP; Dancy BM; Bowers EM; Meyers D; Lareau L; Cole PA; Taverna SD; Alani RM
J Invest Dermatol; 2013 Oct; 133(10):2444-2452. PubMed ID: 23698071
[TBL] [Abstract][Full Text] [Related]
31. The transcriptional co-activators CREB-binding protein (CBP) and p300 play a critical role in cardiac hypertrophy that is dependent on their histone acetyltransferase activity.
Gusterson RJ; Jazrawi E; Adcock IM; Latchman DS
J Biol Chem; 2003 Feb; 278(9):6838-47. PubMed ID: 12477714
[TBL] [Abstract][Full Text] [Related]
32. Is histone acetylation the most important physiological function for CBP and p300?
Bedford DC; Brindle PK
Aging (Albany NY); 2012 Apr; 4(4):247-55. PubMed ID: 22511639
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents.
Yang H; Pinello CE; Luo J; Li D; Wang Y; Zhao LY; Jahn SC; Saldanha SA; Chase P; Planck J; Geary KR; Ma H; Law BK; Roush WR; Hodder P; Liao D
Mol Cancer Ther; 2013 May; 12(5):610-20. PubMed ID: 23625935
[TBL] [Abstract][Full Text] [Related]
34. Assays for Validating Histone Acetyltransferase Inhibitors.
Waddell AR; Liao D
J Vis Exp; 2020 Aug; (162):. PubMed ID: 32831305
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region.
Somasundaram K; El-Deiry WS
Oncogene; 1997 Mar; 14(9):1047-57. PubMed ID: 9070653
[TBL] [Abstract][Full Text] [Related]
36. 3,4-dihydroxytoluene, a metabolite of rutin, suppresses the progression of nonalcoholic fatty liver disease in mice by inhibiting p300 histone acetyltransferase activity.
Lee J; Song JH; Chung MY; Lee JH; Nam TG; Park JH; Hwang JT; Choi HK
Acta Pharmacol Sin; 2021 Sep; 42(9):1449-1460. PubMed ID: 33303988
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes.
Bandyopadhyay D; Okan NA; Bales E; Nascimento L; Cole PA; Medrano EE
Cancer Res; 2002 Nov; 62(21):6231-9. PubMed ID: 12414652
[TBL] [Abstract][Full Text] [Related]
38. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells.
Rahim R; Strobl JS
Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707
[TBL] [Abstract][Full Text] [Related]
39. Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A.
Hamamori Y; Sartorelli V; Ogryzko V; Puri PL; Wu HY; Wang JY; Nakatani Y; Kedes L
Cell; 1999 Feb; 96(3):405-13. PubMed ID: 10025406
[TBL] [Abstract][Full Text] [Related]
40. RNA Binding to CBP Stimulates Histone Acetylation and Transcription.
Bose DA; Donahue G; Reinberg D; Shiekhattar R; Bonasio R; Berger SL
Cell; 2017 Jan; 168(1-2):135-149.e22. PubMed ID: 28086087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
